McCarthy, Derrick
Lofgren, Michael
Watt, Amy
Horton, Holly
Kieffer-Kwon, Philippe
Ding, Jian
Kobold, Sebastian
Baeuerle, Patrick A.
Hofmeister, Robert
Gutierrez, Dario A.
Tighe, Robert
Article History
Received: 4 May 2023
Accepted: 26 September 2023
First Online: 18 October 2023
Declarations
:
: RT, ML, AW, and JD were employees and shareholders of TCR<sup>2</sup> Therapeutics at the time the study was conducted. RT is a current employee of Ankyra Therapeutics. ML and AW are current employees of Adaptimmune, which acquired TCR<sup>2</sup> Therapeutics. JD is a current employee of Myeloid Therapeutics. SK is an inventor of several patents in the field of immuno-oncology, has received honoraria from BMS, GSK, Novartis, TCR<sup>2</sup> Therapeutics, and Miltenyi Biomedicine, received license fees from Carina Biotech and TCR<sup>2</sup> Therapeutics, and received research support from TCR<sup>2</sup> Therapeutics for work related to this manuscript and from Arcus Bioscience, Plectonic GmbH, and Tabby Therapeutics for work unrelated to the manuscript. SK is a former shareholder of TCR<sup>2</sup> Therapeutics, and a current shareholder of Adaptimmune. PAB is a shareholder, scientific advisor, and founder of TCR<sup>2</sup> Therapeutics. RH is a former employee and shareholder of TCR<sup>2</sup> Therapeutics, and a current shareholder of Adaptimmune. DAG is a shareholder at TCR<sup>2</sup> Therapeutics. No competing interests were disclosed by DM, HH and PK-K.
: Consent for publication is not required for these preclinical studies.
: All animal studies were approved by the Institutional Animal Care and Use Committee of Charles River Laboratories under protocol 2021-1261. Human T cells used in these studies were sourced commercially from healthy volunteer donors.